WC
SYRE icon

Wexford Capital’s Spyre Therapeutics SYRE Stock Holding History

Wexford Capital’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$355K Buy
+4,000
New +$292K 0.05% 133
2025
Q2 		– Sell
-38,292
Closed -$618K – 316
2025
Q1 		$618K Buy
+38,292
New +$797K 0.16% 103

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Wexford Capital's SYRE Position: Q2 2026 in Review

Wexford Capital opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 4,000 shares worth $355K. The stake represents 0.05% of the portfolio and ranks #133 among its holdings. This is a return to the name: Wexford Capital previously reported a position in SYRE as recently as Q1 2025.

Wexford Capital first reported a position in SYRE in Q1 2025 and has held it in 2 quarters since. The position peaked at $618K in Q1 2025. 266 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Wexford Capital held 4,000 shares of Spyre Therapeutics worth $355K as of Q2 2026.
  • Spyre Therapeutics was a new Wexford Capital position in Q2 2026.
  • Spyre Therapeutics made up 0.05% of Wexford Capital's portfolio in Q2 2026, its #133 holding.
  • Wexford Capital first reported a position in Spyre Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • Wexford Capital's Spyre Therapeutics position peaked at $618K in Q1 2025.
  • 266 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Wexford Capital's 13F filing for Q2 2026, filed 14 Aug 2026.